TY - JOUR
T1 - The course of peripheral neuropathy and its association with health-related quality of life among colorectal cancer patients
AU - Bonhof, C.S.
AU - van de Poll-Franse, L.V.
AU - Wasowicz, D.K.
AU - Beerepoot, L.V.
AU - Vreugdenhil, G.
AU - Mols, F.
N1 - Funding Information:
The present research was supported by the Center of Research on Psychology in Somatic Disorders (CoRPS), Tilburg University, the Netherlands; the Netherlands Comprehensive Cancer Organisation, Utrecht, the Netherlands; and an Aspasia grant of the Netherlands Organization for Scientific Research (The Hague, The Netherlands). Acknowledgments Novelty and impact
PY - 2021
Y1 - 2021
N2 - Purpose: To gain more insight into the course of chemotherapy-induced peripheral neuropathy (CIPN) and its impact on health-related quality of life (HRQoL) in a population-based sample of colorectal cancer (CRC) patients up to 2 years after diagnosis. Methods: All newly diagnosed CRC patients from four hospitals in the Netherlands were eligible for participation in an ongoing prospective cohort study. Patients (n = 340) completed questions on CIPN (EORTC QLQ-CIPN20) and HRQoL (EORTC QLQ-C30) before initial treatment (baseline) and 1 and 2 years after diagnosis. Results: Among chemotherapy-treated patients (n = 105), a high sensory peripheral neuropathy (SPN) level was reported by 57% of patients at 1 year, and 47% at 2-year follow-up, whereas a high motor peripheral neuropathy (MPN) level was reported by 47% and 28%, at years 1 and 2, respectively. Linear mixed model analyses showed that SPN and MPN symptoms significantly increased from baseline to 1-year follow-up and did not return to baseline level after 2 years. Patients with a high SPN or MPN level reported a worse global quality of life and a worse physical, role, emotional, cognitive, and social functioning compared with those with a low SPN or MPN level. Conclusions:Future studies should focus on understanding the mechanisms underlying CIPN so targeted interventions can be developed to reduce the impact of CIPN on patient’s lives. Implications for cancer survivors: Patients need to be informed of both CIPN and the impact on HRQoL.
AB - Purpose: To gain more insight into the course of chemotherapy-induced peripheral neuropathy (CIPN) and its impact on health-related quality of life (HRQoL) in a population-based sample of colorectal cancer (CRC) patients up to 2 years after diagnosis. Methods: All newly diagnosed CRC patients from four hospitals in the Netherlands were eligible for participation in an ongoing prospective cohort study. Patients (n = 340) completed questions on CIPN (EORTC QLQ-CIPN20) and HRQoL (EORTC QLQ-C30) before initial treatment (baseline) and 1 and 2 years after diagnosis. Results: Among chemotherapy-treated patients (n = 105), a high sensory peripheral neuropathy (SPN) level was reported by 57% of patients at 1 year, and 47% at 2-year follow-up, whereas a high motor peripheral neuropathy (MPN) level was reported by 47% and 28%, at years 1 and 2, respectively. Linear mixed model analyses showed that SPN and MPN symptoms significantly increased from baseline to 1-year follow-up and did not return to baseline level after 2 years. Patients with a high SPN or MPN level reported a worse global quality of life and a worse physical, role, emotional, cognitive, and social functioning compared with those with a low SPN or MPN level. Conclusions:Future studies should focus on understanding the mechanisms underlying CIPN so targeted interventions can be developed to reduce the impact of CIPN on patient’s lives. Implications for cancer survivors: Patients need to be informed of both CIPN and the impact on HRQoL.
KW - CHEMOTHERAPY
KW - Colorectal cancer
KW - Health-related quality of life
KW - OXALIPLATIN
KW - PROFILES
KW - Peripheral neuropathy
KW - QUESTIONNAIRE
KW - SURVIVORS
UR - http://www.scopus.com/inward/record.url?scp=85096008410&partnerID=8YFLogxK
U2 - 10.1007/s11764-020-00923-6
DO - 10.1007/s11764-020-00923-6
M3 - Article
SN - 1932-2259
VL - 15
SP - 190
EP - 200
JO - Journal of Cancer Survivorship
JF - Journal of Cancer Survivorship
IS - 2
ER -